Short Interest in NeuroMetrix, Inc. (NASDAQ:NURO) Decreases By 48.1%

Posted by Teresa Graham on Mar 4th, 2025

NeuroMetrix, Inc. (NASDAQ:NURO – Get Free Report) was the recipient of a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 1,400 shares, a decline of 48.1% from the January 31st total of 2,700 shares. Based on an average daily volume of 20,600 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.1% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on NeuroMetrix in a report on Monday, February 24th. They issued a “sell” rating for the company.

View Our Latest Report on NeuroMetrix

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NeuroMetrix stock. Renaissance Technologies LLC purchased a new position in shares of NeuroMetrix, Inc. (NASDAQ:NURO – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned about 0.57% of NeuroMetrix as of its most recent SEC filing. 19.40% of the stock is currently owned by institutional investors and hedge funds.

NeuroMetrix Price Performance

NURO traded down $0.02 on Monday, hitting $4.36. The company had a trading volume of 26,232 shares, compared to its average volume of 16,458. The company’s fifty day moving average price is $4.18 and its 200 day moving average price is $4.05. NeuroMetrix has a 1-year low of $2.66 and a 1-year high of $4.73. The stock has a market cap of $8.95 million, a price-to-earnings ratio of -0.95 and a beta of 2.18.

NeuroMetrix Company Profile

(Get Free Report)

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.